1   # Supplementary Figures

2

3   **Impact of Oncotype DX testing on ER-positive breast cancer treatment and survival in the first**

4   **decade of use**

5   Evelien Schaafsma, Baoyi Zhang, Merit Schaafsma, Chun-Yip Tong, Lanjing Zhang, Chao Cheng

6

Suppl. Figure 1. **Oncotype DX usage rates and hazard ratios stratified by grade. A.** Oncotype DX

usage rate among the three breast cancer grades. Usage rates were calculated based on the total number of

patients within each indicated grade group. **B.** Hazard ratios of Oncotype DX usage stratified by tumor

grade between 2004 and 2015 from univariate Cox regression models.

Suppl. Figure 2. **Oncotype DX score is predictive of patient's survival in Luminal A and Luminal B breast cancer. A.** Survival plot of 3 risk groups classified by Oncotype DX (BCSS) in Luminal A breast cancer. **B.** Survival plot of 3 risk groups classified by Oncotype DX (OS) in Luminal A breast cancer. **C.** Survival plot of 3 risk groups classified by Oncotype DX (BCSS) in Luminal B breast cancer. **D.** Survival plot of 3 risk groups classified by Oncotype DX (OS) in Luminal B breast cancer.